DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity

Journal of Immunology

Volumn 198, Issue 4, 2017, Pages 1649-1659

  Kitai, Yuichi ^a,b   Kawasaki, Takumi ^b   Sueyoshi, Takuya ^b   Kobiyama, Kouji ^c,d,f   Ishii, Ken J ^c,d   Zou, Jian ^c,e   Akira, Shizuo ^c,e   Matsuda, Tadashi ^a   Kawai, Taro ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d Health and Nutrition   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOPOTECAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA; DNA TOPOISOMERASE INHIBITOR; MPYS PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTITUMOR IMMUNITY; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME PHOSPHORYLATION; EXOSOME; FEMALE; IMMUNITY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIGAND BINDING; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ANIMAL; DEFICIENCY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DNA, NEOPLASM; EXOSOMES; FEMALE; IMMUNITY, INNATE; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 85014610090     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601694     Document Type: Article

References (56)

1. Kawai, T., and S. Akira. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650.
2. Crişan, T. O., M. G. Netea, and L. A. Joosten. 2016. Innate immune memory: implications for host responses to damage-associated molecular patterns. Eur. J. Immunol. 46: 817-828.
3. Guescini, M., D. Guidolin, L. Vallorani, L. Casadei, A. M. Gioacchini, P. Tibollo, M. Battistelli, E. Falcieri, L. Battistin, L. F. Agnati, and V. Stocchi. 2010. C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction. Exp. Cell Res. 316: 1977-1984.
4. McCarthy, C. M., and L. C. Kenny. 2016. Immunostimulatory role of mitochondrial DAMPs: alarming for pre-eclampsia? Am. J. Reprod. Immunol. 76: 341-347.
5. Pandolfi, F., S. Altamura, S. Frosali, and P. Conti. 2016. Key role of DAMP in inflammation, cancer, and tissue repair. Clin. Ther. 38: 1017-1028.
6. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
7. Zou, J., T. Kawai, T. Tsuchida, T. Kozaki, H. Tanaka, K. S. Shin, H. Kumar, and S. Akira. 2013. Poly IC triggers a cathepsin D-and IPS-1-dependent pathway to enhance cytokine production and mediate dendritic cell necroptosis. Immunity 38: 717-728.
8. Ma, Y., S. Adjemian, S. R. Mattarollo, T. Yamazaki, L. Aymeric, H. Yang, J. P. Portela Catani, D. Hannani, H. Duret, K. Steegh, et al. 2013. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigenpresenting cells. Immunity 38: 729-741.
9. Fucikova, J., P. Kralikova, A. Fialova, T. Brtnicky, L. Rob, J. Bartunkova, and R. Sṕsek. 2011. Human tumor cells killed by anthracyclines induce a tumorspecific immune response. Cancer Res. 71: 4821-4833.
10. Gehrke, N., C. Mertens, T. Zillinger, J. Wenzel, T. Bald, S. Zahn, T. Tuting, G. Hartmann, and W. Barchet. 2013. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STINGdependent immune sensing. Immunity 39: 482-495.
11. Cai, X., Y. H. Chiu, and Z. J. Chen. 2014. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol. Cell 54: 289-296.
12. Woo, S. R., M. B. Fuertes, L. Corrales, S. Spranger, M. J. Furdyna, M. Y. Leung, R. Duggan, Y. Wang, G. N. Barber, K. A. Fitzgerald, et al. 2014. STINGdependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. [Published erratum appears in 2015 Immunity 42: 199.] Immunity 41: 830-842.
13. Deng, L., H. Liang, M. Xu, X. Yang, B. Burnette, A. Arina, X. D. Li, H. Mauceri, M. Beckett, T. Darga, et al. 2014. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41: 843-852.
14. Demaria, O., A. De Gassart, S. Coso, N. Gestermann, J. Di Domizio, L. Flatz, O. Gaide, O. Michielin, P. Hwu, T. V. Petrova, et al. 2015. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl. Acad. Sci. USA 112: 15408-15413.
15. Staker, B. L., K. Hjerrild, M. D. Feese, C. A. Behnke, A. B. Burgin, Jr., and L. Stewart. 2002. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA 99: 15387-15392.
16. Sauer, J. D., K. Sotelo-Troha, J. von Moltke, K. M. Monroe, C. S. Rae, S. W. Brubaker, M. Hyodo, Y. Hayakawa, J. J. Woodward, D. A. Portnoy, and R. E. Vance. 2011. The N-ethyl-N-nitrosourea-induced goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 79: 688-694.
17. Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122.
18. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643.
19. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of gramnegative and gram-positive bacterial cell wall components. Immunity 11: 443-451.
20. Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, and S. Akira. 1999. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162: 3749-3752.
21. Kumar, H., T. Kawai, H. Kato, S. Sato, K. Takahashi, C. Coban, M. Yamamoto, S. Uematsu, K. J. Ishii, O. Takeuchi, and S. Akira. 2006. Essential role of IPS-1 in innate immune responses against RNA viruses. J. Exp. Med. 203: 1795-1803.
22. Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, M. Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13: 539-548.
23. Kitai, Y., O. Takeuchi, T. Kawasaki, D. Ori, T. Sueyoshi, M. Murase, S. Akira, and T. Kawai. 2015. Negative regulation of melanoma differentiation-associated gene 5 (MDA5)-dependent antiviral innate immune responses by Arf-like protein 5B. J. Biol. Chem. 290: 1269-1280.
24. Saitoh, T., N. Fujita, T. Hayashi, K. Takahara, T. Satoh, H. Lee, K. Matsunaga, S. Kageyama, H. Omori, T. Noda, et al. 2009. Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc. Natl. Acad. Sci. USA 106: 20842-20846.
25. Tanaka, H., H. Matsushima, A. Nishibu, B. E. Clausen, and A. Takashima. 2009. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 69: 6987-6994.
26. Zitvogel, L., L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8: 59-73.
27. Stetson, D. B., J. S. Ko, T. Heidmann, and R. Medzhitov. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134: 587-598.
28. Kawane, K., H. Fukuyama, G. Kondoh, J. Takeda, Y. Ohsawa, Y. Uchiyama, and S. Nagata. 2001. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science 292: 1546-1549.
29. Tominaga, N., N. Kosaka, M. Ono, T. Katsuda, Y. Yoshioka, K. Tamura, J. Lötvall, H. Nakagama, and T. Ochiya. 2015. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6: 6716.
30. Kosaka, N. 2016. Decoding the secret of cancer by means of extracellular vesicles. J. Clin. Med. 5: 22.
31. Hoshino, A., B. Costa-Silva, T. L. Shen, G. Rodrigues, A. Hashimoto, M. Tesic Mark, H. Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, et al. 2015. Tumour exosome integrins determine organotropic metastasis. Nature 527: 329-335.
32. Thakur, B. K., H. Zhang, A. Becker, I. Matei, Y. Huang, B. Costa-Silva, Y. Zheng, A. Hoshino, H. Brazier, J. Xiang, et al. 2014. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24: 766-769.
33. Dreux, M., U. Garaigorta, B. Boyd, E. Décembre, J. Chung, C. Whitten-Bauer, S. Wieland, and F. V. Chisari. 2012. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 12: 558-570.
34. Cliby, W. A., K. A. Lewis, K. K. Lilly, and S. H. Kaufmann. 2002. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 277: 1599-1606.
35. Tanaka, T., A. Kurose, X. Huang, W. Dai, and Z. Darzynkiewicz. 2006. ATM activation and histone H2AX phosphorylation as indicators of DNA damage by DNA topoisomerase I inhibitor topotecan and during apoptosis. Cell Prolif. 39: 49-60.
36. Jorgensen, I., and E. A. Miao. 2015. Pyroptotic cell death defends against intracellular pathogens. Immunol. Rev. 265: 130-142.
37. Yatim, N., H. Jusforgues-Saklani, S. Orozco, O. Schulz, R. Barreira da Silva, C. Reis e Sousa, D. R. Green, A. Oberst, and M. L. Albert. 2015. RIPK1 and NFkB signaling in dying cells determines cross-priming of CD8+ T cells. Science 350: 328-334.
38. Wei, F., Y. Xie, L. Tao, and D. Tang. 2010. Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell. Signal. 22: 1783-1789.
39. Shalapour, S., and M. Karin. 2015. Immunity, inflammation, and cancer: an eternal fight between good and evil. J. Clin. Invest. 125: 3347-3355.
40. Song, L., M. A. Smith, P. Doshi, K. Sasser, W. Fulp, S. Altiok, and E. B. Haura. 2014. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J. Thorac. Oncol. 9: 974-982.
41. Hodge, D. R., E. M. Hurt, and W. L. Farrar. 2005. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41: 2502-2512.
42. Wei, L. H., M. L. Kuo, C. A. Chen, C. H. Chou, K. B. Lai, C. N. Lee, and C. Y. Hsieh. 2003. Interleukin-6 promotes cervical tumor growth by VEGFdependent angiogenesis via a STAT3 pathway. Oncogene 22: 1517-1527.
43. Fuertes, M. B., S. R. Woo, B. Burnett, Y. X. Fu, and T. F. Gajewski. 2013. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34: 67-73.
44. Rizza, P., F. Moretti, I. Capone, and F. Belardelli. 2015. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev. 26: 195-201.
45. Liu, M., S. Guo, and J. K. Stiles. 2011. The emerging role of CXCL10 in cancer (Review). Oncol. Lett. 2: 583-589.
46. Sangfelt, O., S. Erickson, and D. Grander. 2000. Mechanisms of interferoninduced cell cycle arrest. Front. Biosci. 5: D479-D487.
47. Bonavita, O., M. Massara, and R. Bonecchi. 2016. Chemokine regulation of neutrophil function in tumors. Cytokine Growth Factor Rev. 30: 81-86.
48. Lespagnol, A., D. Duflaut, C. Beekman, L. Blanc, G. Fiucci, J. C. Marine, M. Vidal, R. Amson, and A. Telerman. 2008. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 15: 1723-1733.
49. Guescini, M., S. Genedani, V. Stocchi, and L. F. Agnati. 2010. Astrocytes and glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna) 117: 1-4.
50. Bridgeman, A., J. Maelfait, T. Davenne, T. Partridge, Y. Peng, A. Mayer, T. Dong, V. Kaever, P. Borrow, and J. Rehwinkel. 2015. Viruses transfer the antiviral second messenger cGAMP between cells. Science 349: 1228-1232.
51. Whitmore, M. M., M. J. DeVeer, A. Edling, R. K. Oates, B. Simons, D. Lindner, and B. R. Williams. 2004. Synergistic activation of innate immunity by doublestranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64: 5850-5860.
52. Cheng, Y. S., and F. Xu. 2010. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol. Ther. 10: 1219-1223.
53. Matsumoto, M., M. Tatematsu, F. Nishikawa, M. Azuma, N. Ishii, A. Morii-Sakai, H. Shime, and T. Seya. 2015. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat. Commun. 6: 6280.
54. Trojandt, S., D. Knies, S. Pektor, S. Ritz, V. Mailänder, S. Grabbe, A. B. Reske-Kunz, and M. Bros. 2013. The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells. Cancer Immunol. Immunother. 62: 1315-1326.
55. Rialdi, A., L. Campisi, N. Zhao, A. C. Lagda, C. Pietzsch, J. S. Ho, L. Martinez-Gil, R. Fenouil, X. Chen, M. Edwards, et al. 2016. Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science 352: aad7993.
56. Barreto, J. N., K. B. McCullough, L. L. Ice, and J. A. Smith. 2014. Antineoplastic agents and the associated myelosuppressive effects: a review. J. Pharm. Pract. 27: 440-446.